Anzeige
Mehr »
Dienstag, 17.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
Dow Jones News
236 Leser
Artikel bewerten:
(0)

EQS-News: Union Medical Healthcare wins award 'Excellence in Innovation in Medical Aesthetic Market (Asia Pacific)' from Frost & Sullivan for professionalism and innovative spirit

Dow Jones received a payment from EQS/DGAP to publish this press release.

EQS-News / 26/09/2017 / 10:29 UTC+8 
 
*[For Immediate Release]* 
 
*Union Medical Healthcare wins award "Excellence in Innovation in Medical 
Aesthetic Market (Asia Pacific)" from Frost & Sullivan for professionalism 
and innovative spirit 
Consolidates the Group's leading position in the industry* 
 
(25 September, 2017) Union Medical Healthcare Limited ("Union Medical 
Healthcare" or the "Company", which together with its subsidiaries, is 
referred to as the "Group", SEHK stock code: 2138), the leading aesthetic 
medical service provider in Hong Kong, is pleased to announce that the Group 
has received an award, the "Excellence in Innovation in Medical Aesthetic 
Market (Asia Pacific)" from the renowned global consulting firm Frost & 
Sullivan in "Growth, Innovation and Leadership Best Practice Award Ceremony 
for Listed Company 2017". The accolade was presented to the Group in 
recognition of its consistent innovation endeavours that promote the 
professionalism of the industry. 
 
"Growth, Innovation and Leadership Best Practice Award for Listed Company" 
is aimed at celebrating companies which have exemplary achievements in 
leadership, innovation, client servicing and product development. A Frost & 
Sullivan team judged the competition and decided on the winners who were 
outstanding brands. 
 
*Mr. Eddy Tang, Chairman, Executive Director and Chief Executive Officer of 
Union Medical Healthcare* said, "It is a great honour to have been awarded 
the 'Excellence in Innovation in Medical Aesthetic Market (Asia Pacific)'. 
The award represents recognition of the Group's outstanding performance by a 
professional organization and the market. Looking ahead, the Group will 
continue to exert influence as an industry leader by introducing more 
innovative and safe products and services into the market. Such initiative 
will help to consolidate the Group's leading position in the market for 
aesthetic medical services and further promote Hong Kong as a hub of medical 
aesthetics in Asia Pacific." 
 
-End- 
 
*About Union Medical Healthcare Limited* 
Union Medical Healthcare is principally engaged in the provision of one-stop 
aesthetic medical, beauty and health management solutions with 38 clinics 
and servicing centres across Hong Kong, the PRC and Macao as at 31 May 2017. 
In 2016, the Group obtained the Hong Kong Top Service Brand and opened 
re:HEALTH, a one-stop health management centre, to provide a full range of 
services and products, including comprehensive health screening, health 
product and health management services. The Group is the largest aesthetic 
medical service provider in Hong Kong in terms of revenue. The Group ranked 
first in Hong Kong from 2012 to 2016 in terms of the number of aesthetic 
injection procedures performed involving utilization of the top-six 
revenue-generating aesthetic medications in Hong Kong; and was the Black 
Diamond Provider of the transparent orthodontic device for teeth alignment, 
Invisalign(R), in 2015 and 2016. The Group has successfully built DR REBORN, 
a well-recognized brand in Hong Kong, with the reputation of being a premier 
provider of aesthetic medical services in Hong Kong. 
 
*For further information, please contact: 
iPR Ogilvy & Mather* 
Callis Lau / Molisa Lau / Maggie Chui / Francesca Yeung 
Tel: (852) 2136 6952 / 2136 6953 / 2136 8059 / 3920 7639 
Fax: (852) 3170 6606 
Email: umh@iprogilvy.com 
 
Document: http://n.eqs.com/c/fncls.ssp?u=MRPEHXVCVL [1] 
Document title: Mr. Gabriel Lee, Executive Director and Chief Operating 
Officer of Union Medical Healthcare (right) accepts an award 'Excellence in 
Innovation in Medical Aesthetic Market (Asia Pacific)'. 
 
26/09/2017 Dissemination of a Marketing Press Release, transmitted by EQS 
Group. 
The issuer is solely responsible for the content of this announcement. 
 
Media archive at www.todayir.com 
 
1: http://public-cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=6ff37b69c04dd19fa132d2dce4744358&application_id=612819&site_id=vwd&application_name=news 
 

(END) Dow Jones Newswires

September 25, 2017 22:29 ET (02:29 GMT)

© 2017 Dow Jones News
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.